JP2017526625A5 - - Google Patents

Download PDF

Info

Publication number
JP2017526625A5
JP2017526625A5 JP2016574456A JP2016574456A JP2017526625A5 JP 2017526625 A5 JP2017526625 A5 JP 2017526625A5 JP 2016574456 A JP2016574456 A JP 2016574456A JP 2016574456 A JP2016574456 A JP 2016574456A JP 2017526625 A5 JP2017526625 A5 JP 2017526625A5
Authority
JP
Japan
Prior art keywords
nucleic acid
region
polypeptide
protein dimer
pharmaceutically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016574456A
Other languages
English (en)
Japanese (ja)
Other versions
JP6687548B2 (ja
JP2017526625A (ja
Filing date
Publication date
Priority claimed from GBGB1411506.7A external-priority patent/GB201411506D0/en
Application filed filed Critical
Publication of JP2017526625A publication Critical patent/JP2017526625A/ja
Publication of JP2017526625A5 publication Critical patent/JP2017526625A5/ja
Application granted granted Critical
Publication of JP6687548B2 publication Critical patent/JP6687548B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016574456A 2014-06-27 2015-06-26 変性された潜在関連蛋白質構成物 Expired - Fee Related JP6687548B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1411506.7A GB201411506D0 (en) 2014-06-27 2014-06-27 Modified latency associated protein construct
GB1411506.7 2014-06-27
PCT/GB2015/051877 WO2015198072A1 (en) 2014-06-27 2015-06-26 Modified latency associated protein construct

Publications (3)

Publication Number Publication Date
JP2017526625A JP2017526625A (ja) 2017-09-14
JP2017526625A5 true JP2017526625A5 (enExample) 2018-06-28
JP6687548B2 JP6687548B2 (ja) 2020-04-22

Family

ID=51410274

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016574456A Expired - Fee Related JP6687548B2 (ja) 2014-06-27 2015-06-26 変性された潜在関連蛋白質構成物

Country Status (5)

Country Link
US (2) US10435451B2 (enExample)
EP (1) EP3160992B1 (enExample)
JP (1) JP6687548B2 (enExample)
GB (1) GB201411506D0 (enExample)
WO (1) WO2015198072A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202004679D0 (en) 2020-03-31 2020-05-13 Stealthyx Therapeutics Ltd Modified latercy associated protein construct
JP2023520922A (ja) * 2020-04-10 2023-05-22 シートムエックス セラピューティクス，インコーポレイテッド 活性化可能サイトカイン構築物および関連組成物ならびに方法
CA3189545A1 (en) * 2020-07-17 2022-01-20 The University Of Western Australia Compositions and methods for the treatment of cancer
CA3211924A1 (en) 2021-03-16 2022-09-22 Sayantan Mitra Masked activatable cytokine constructs and related compositions and methods
CN120603603A (zh) * 2023-01-12 2025-09-05 瑞泽恩制药公司 用于靶向递送TGFβ的组合物和方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284763A (en) 1985-03-22 1994-02-08 Genentech, Inc. Nucleic acid encoding TGF-β and its uses
US5697901A (en) 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection
GB0100551D0 (en) * 2001-01-09 2001-02-21 Queen Mary & Westfield College Protein
WO2002059317A2 (en) * 2001-01-24 2002-08-01 Zymogenetics, Inc. Cub domain protein zcub3 and materials and methods for making it
WO2007044321A2 (en) * 2005-10-04 2007-04-19 Greenville Hospital System Latent procytotoxins and uses thereof
GB0724556D0 (en) 2007-12-17 2008-01-30 Queen Mary & Westfield College LAtency associated protein construct with aggrecanase sensitive cleavage site
EP2377888A1 (en) * 2010-04-07 2011-10-19 Corimmun GmbH Fusion protein

Similar Documents

Publication Publication Date Title
MX2022011411A (es) Proteinas de union a antigeno que se unen especificamente a mage-a.
WO2019002444A9 (en) NEW T CELL RECEPTORS AND IMMUNOTHERAPY USING THE SAME
JP2014503198A5 (enExample)
JP7536294B2 (ja) 抗体のＦｃ領域改変体
IL261432B1 (en) Induced binding proteins and methods of use
JP2012505902A5 (enExample)
TW201129379A (en) Anti-Orai1 antigen binding proteins and uses thereof
JP2016526909A5 (enExample)
WO2015188132A8 (en) Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof
HRP20231118T1 (hr) Sintetizirani polipeptidi koji vežu transferinske receptore
US20130012436A1 (en) Fibronectin based scaffold domain proteins that bind il-23
WO2005024044A3 (en) Method for the production of fusion proteins in transgenic mammal milk
BR0213565A (pt) Anticorpo de anti-tnf alfa modificado
WO2007130455A3 (en) Compositions and methods for treatment of non-hodgkins lymphoma
JP2017501728A5 (enExample)
JP2014510518A5 (enExample)
JP2015504052A5 (enExample)
WO2007126798A3 (en) Regulated expression of recombinant proteins from adeno-associated viral vectors
RU2015152077A (ru) Тримерные антигенсвязывающие молекулы
RU2018141360A (ru) Contorsbody - одноцепочечный связывающий мишень агент
ATE517118T1 (de) Bis-met-histone
WO2008136736A3 (en) Immunoregulatory structures from normally occurring proteins
CA3195315A1 (en) Compositions and methods for selective depletion of target molecules
CN105658228B (zh) 结合人类补体c5的稳定多肽
WO2007018619A3 (en) Chimeric therapeutic agents